Adial Pharmaceuticals (ADIL) Long-Term Deferred Tax (2017 - 2024)
Adial Pharmaceuticals (ADIL) posted Long-Term Deferred Tax of $15.6 million for Q4 2024, up 26.86% sequentially from $12.3 million in Q4 2023, and up 26.86% YoY from $12.3 million in Q1 2024.
Adial Pharmaceuticals (ADIL) Long-Term Deferred Tax (2017 - 2024) Analysis & Trends
Adial Pharmaceuticals has reported Long-Term Deferred Tax for 8 years, with the latest figure at $15.6 million in Q4 2024.
- Quarterly Long-Term Deferred Tax rose 26.86% year-over-year to $15.6 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $15.6 million (up 26.86% YoY) and the FY2024 annual result came in at $15.6 million, up 26.86% from the prior year.
- Long-Term Deferred Tax rose to $15.6 million in Q4 2024 per ADIL's latest filing, from $12.3 million in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $15.6 million in Q4 2024 and troughed at $384.0 in Q4 2022.
- A 5-year average of $6.8 million and a median of $6.0 million in 2020 frame the typical range for Long-Term Deferred Tax.
- The sharpest annual moves came in 2022 and 2023: Long-Term Deferred Tax sank 99.76% in 2022, then jumped 3202295.31% in 2023.
- Over 5 years, Long-Term Deferred Tax stood at $6.0 million in 2020, then slumped by 97.35% to $158913.0 in 2021, then tumbled by 99.76% to $384.0 in 2022, then surged by 3202295.31% to $12.3 million in 2023, then increased by 26.86% to $15.6 million in 2024.
- According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $15.6 million, $12.3 million, and $384.0 for Q4 2024, Q4 2023, and Q4 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Adial Pharmaceuticals | 29.02 Mn | 29.02 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 15.60 Mn |
| Dec 31, 2023 | 12.30 Mn |
| Dec 31, 2022 | 384.00 |
| Dec 31, 2021 | 158,913.00 |
| Dec 31, 2020 | 6.00 Mn |
| Dec 31, 2019 | 14.12 Mn |
| Dec 31, 2018 | 7.13 Mn |
| Dec 31, 2017 | 404,000.00 |